Skip to main
VVOS
VVOS logo

Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics (VVOS) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vivos Therapeutics Inc. has reported a significant increase in operating expenses, rising 52% year-over-year to $7 million in Q2 FY25, highlighting substantial investment in growth and innovation. The company is transitioning to a new business model that promises to enhance revenue potential by 4-6 times per case while providing access to a larger patient base and maintaining healthy profit margins. Moreover, following successful pilot results with Rebis Health, Vivos is actively seeking partnerships and acquisitions with sleep test centers, indicating strong strategic growth initiatives in the market for sleep-disordered breathing solutions.

Bears say

Vivos Therapeutics Inc. reported revenues of $3.8 million for Q2 FY25, which fell short of the estimated $4.2 million and reflected a 6% year-over-year decline despite a 27% quarter-over-quarter increase. The company has revised its FY25 earnings per share (EPS) estimates down to $(2.13) from $(1.54) due to rising operating expenses, contributing to a pro forma EPS of $(0.55) that also missed prior expectations. Additionally, the company faces risks related to low visibility in financial performance and the potential for further dilution from financing activities.

Vivos Therapeutics (VVOS) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vivos Therapeutics (VVOS) Forecast

Analysts have given Vivos Therapeutics (VVOS) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Vivos Therapeutics (VVOS) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vivos Therapeutics (VVOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.